NextVivo is a biotech company developing an immune organoid technology platform.
NextVivo has raised $7.9M in total funding. The most recent round was Seed. The last funding was announced in December 2021.
NextVivo's investors include Khosla Ventures, Alexandria Venture Investments, Peregrine Ventures, Wilson Sonsini Goodrich & Rosati.
NextVivo is headquartered in Palo Alto, United States.
NextVivo is a biotech company developing an immune organoid technology platform.
NextVivo is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"NextVivo — Funding & Investors." VCBacked, December 9, 2021, https://www.vcbacked.co/company/nextvivo. Accessed September 29, 2026.
VCBacked. (2021). NextVivo — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/nextvivo
{{cite web |title=NextVivo — Funding & Investors |url=https://www.vcbacked.co/company/nextvivo |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated